ライフサイエンスコーパス: CARM1

1 CARM1 and p300 cooperate with BRCA1 and p53 to induce ex

2 CARM1 and PRMT1 are transcriptional coactivators that de

3 CARM1 contains a conserved protein arginine methyltransf

4 CARM1 facilitated Tax transactivation of the CREB-depend

5 CARM1 is an arginine methyltransferase with diverse hist

6 CARM1 is one of nine protein arginine methyltransferases

7 CARM1 is recruited by many different transcription facto

8 CARM1 is specifically required for the estrogen-induced

9 CARM1 methylates histone H3 and other factors including

10 CARM1 methyltransferase activity was required for induct

11 CARM1 overexpression has been reported in multiple cance

12 CARM1 recruitment lags behind the binding of SRC-3 and p

13 CARM1 regulates this nuclear retention pathway at two le

14 CARM1 requires its enzymatic activity for all of its kno

15 CARM1 selective hits were further validated by orthogona

16 CARM1 synergizes with CIITA in activating MHC-II transcr

17 CARM1 was evidenced as an ERalpha coactivator in cell-ba

18 CARM1 was localized in hippocampal post-synapses, with i

19 CARM1, which is necessary for MCP-1 expression, was not

20 tor-associated arginine methyltransferase 1 (CARM1) action are critical to E2-stimulated gene express

21 tor-associated arginine methyltransferase 1 (CARM1) activity.

22 tor-associated arginine methyltransferase 1 (CARM1) and prevents its correct cellular localization du

23 es coactivator arginine methyltransferase 1 (CARM1) and protein arginine methyltransferase 6 (PRMT6)

24 tor-associated arginine methyltransferase 1 (CARM1) as a crucial component of autophagy in mammals.

25 tor-associated arginine methyltransferase 1 (CARM1) blocks CREB activation by disabling the interacti

26 tor-associated arginine methyltransferase 1 (CARM1) has been proposed as a basis for its ability to e

27 tor-associated arginine methyltransferase 1 (CARM1) is a coactivator for a number of transcription fa

28 tor-associated arginine methyltransferase 1 (CARM1) is a dual functional coregulator that facilitates

29 tor associated arginine methyltransferase 1 (CARM1) is a member of the protein arginine methyltransfe

30 tor-associated arginine methyltransferase 1 (CARM1) is a propitious target for cancer therapy; howeve

31 tor-associated arginine methyltransferase 1 (CARM1) is a protein arginine methyltransferase that meth

32 tor-associated arginine methyltransferase 1 (CARM1) is a protein methyltransferase that negatively re

33 tor-associated arginine methyltransferase 1 (CARM1) is subjected to multiple post-translational modif

34 tor-associated arginine methyltransferase 1 (CARM1) methylates Arg 754 in the KIX region of coactivat

35 tor-associated arginine methyltransferase 1 (CARM1), a coactivator for various cancer-relevant transc

36 tor-associated arginine methyltransferase 1 (CARM1), a protein-arginine methyltransferase previously

37 tor-associated arginine methyltransferase 1 (CARM1), a unique coactivator of ERalpha that can simulta

38 tor-associated arginine methyltransferase 1 (CARM1), both in in vitro and cellular settings.

39 tor-associated arginine methyltransferase 1 (CARM1), providing insight into the unrecognized function

40 tor-associated arginine methyltransferase 1 (CARM1), the histone arginine methyltransferase and coact

41 tor-associated arginine methyltransferase 1 (CARM1), which methylates histone H3 and other proteins s

42 tor-associated arginine methyltransferase 1 (CARM1)-mediated histone methylation has been shown to ac

43 tor-associated arginine methyltransferase 1 (CARM1).

44 tor-associated arginine methyltransferase 1 (CARM1).

45 tor-associated arginine methyltransferase 1 (CARM1/PRMT4) binds the p160 family of steroid receptor c

46 tor-associated arginine methyltransferase 1, CARM1.

47 virtual screening approaches, we identify 11 CARM1 (PRMT4) inhibitors with ligand efficiencies rangin

48 We identified >130 CARM1 protein substrates and validated in vitro >90% of

49 thylation promotes dissociation of the SRC-3/CARM1 coactivator complex.

50 the spinal muscular atrophy protein SMN in a CARM1-dependent fashion.

51 uited to an estrogen-responsive element in a CARM1-dependent manner.

52 differentiation of Carm1(-/-) FL cells in a CARM1-sufficient host showed that CARM1 is required cell

53 oorly to and did not cooperate with PRMT1, a CARM1-related protein arginine methyltransferase that al

54 nds of optimization produced 27 (SGC2085), a CARM1 inhibitor with an IC50 of 50 nM and more than hund

55 Following these events, K23 is acetylated, CARM1 associates with chromatin, and methylation at R17

56 In adults, CARM1 is overexpressed in human grade-III breast tumors

57 Although CARM1 and its asymmetrically deposited dimethylation at

58 Although CARM1 is expressed in the neural crest region in early d

59 Significant synergy was observed among CARM1, p300 and GRIP1, which is dependent on the interac

60 ear factor (NF)-kappaB signaling (CARD14 and CARM1).

61 pts encoding full-length CARM1 (CARM1FL) and CARM1 with exon 15 deleted (CARM1DeltaE15) exist in cell

62 tic coactivator function of beta-catenin and CARM1 is not restricted to steroid receptors because the

63 tor and secondary coactivators, p300/CBP and CARM1.

64 ated with a simultaneous increase of FXR and CARM1 occupation.

65 h other NR coactivators, including GRIP1 and CARM1, to enhance estrogen receptor function.

66 which, with the help of CARM1 inhibitor and CARM1 morpholinos, we show that inhibition of H3R17 meth

67 MYPT1 and CARM1 also function to alter OGT substrate specificity i

68 We demonstrate here that MYPT1 and CARM1 also interact with and target OGT.

69 MYPT1 and CARM1 are substrates of OGT in vitro and in vivo.

70 is dependent on the interaction of p300 and CARM1 with the AD1 and AD2 domains of GRIP1, respectivel

71 or coactivator synergy among p160, p300, and CARM1 coactivators.

72 erophospholipid metablism, h-Efp pathway and CARM1 and Regulation of Estrogen Receptor, which can be

73 ct PRMT2 differs from coactivators PRMT1 and CARM1 (coactivator-associated arginine methyltransferase

74 rotein arginine methyltransferases PRMT1 and CARM1 in p53 function; (2) both independent and ordered

75 methyltransferases, G9a, SUV39H1, PRMT1 and CARM1.

76 ed cooperative functions of p300, PRMT1, and CARM1; and (3) mechanisms that involve direct interactio

77 physical interaction between HTLV-1 Tax and CARM1 was demonstrated using in vitro glutathione S-tran

78 As CARM1 is a potent transcriptional coactivator of estroge

79 s is the first report of compounds acting as CARM1 activators.

80 V-1 LTR through a direct interaction between CARM1 and Tax and this binding promotes methylation of h

81 ast two-hybrid screen for proteins that bind CARM1 identified the protein Flightless I (Fli-I), which

82 t its enzymatic activity, it did impair both CARM1-activated transcription and pre-mRNA splicing.

83 Therefore, histone methylation at Arg-17 by CARM1 is a downstream target of signaling through ligand

84 s in the transcription initiation complex by CARM1 occurs along with acetylation of histones and othe

85 he increased occupation of the BSEP locus by CARM1 also corresponds with the increased deposition of

86 n of splicing factors that are methylated by CARM1, and protein-protein interactions that are regulat

87 factors that are specifically methylated by CARM1.

88 us, arginine-specific histone methylation by CARM1 is an important part of the transcriptional activa

89 600 is a site for regulatory methylation by CARM1/PRMT4, which negates the CREB-binding function of

90 and site specificity of its modification by CARM1.

91 e required methylation of Arg 754 of p300 by CARM1.

92 n-protein interactions that are regulated by CARM1, strongly implicates this enzyme in the regulation

93 onal and temporal relationships among CIITA, CARM1, and CBP for IFN-gamma induction of MHC-II.

94 strates the coordinated regulation of CIITA, CARM1, and the acetyltransferase cyclic-AMP response ele

95 A kinetic analysis shows that CIITA, CARM1, and H3-R17 methylation all precede CBP loading on

96 ions enhanced the binding of the coactivator CARM1 to the distal regulatory region.

97 uding those sites methylated by coactivators CARM1 (H3 Arg17) and PRMT1 (H4 Arg3).

98 ediated enhanced recruitment of coactivators CARM1 and p300 to GR target genes.

99 dependent activation of the ERalpha-cofactor CARM1.

100 serves as a molecular switch for controlling CARM1 enzymatic activity during the cell cycle.

101 when an arginine methyltransferase-defective CARM1 mutant is used.

102 ysine to create an automethylation-deficient CARM1.

103 tide sequences derived from the well-defined CARM1 substrate poly(A)-binding protein 1 (PABP1) were c

104 Furthermore, either CARM1 knockdown or CARM1 enzyme-deficient mutant knockin

105 In the process of purifying endogenous CARM1-interacting proteins, we identified an associated

106 Although the histone methylation enzyme CARM1 and an ATP-remodeling complex have been individual

107 ious target for cancer therapy; however, few CARM1 substrates are known, and its mechanism of substra

108 Consistent with these findings, CARM1 led to increased BSEP promoter activity with an in

109 R26-methylase CARM1 and is lowered following CARM1 inhibition, indicating the importance of epigeneti

110 icing not only serves as the determinant for CARM1 automethylation but also generates cell type-speci

111 ledge, the first demonstration of a role for CARM1 in multiple myeloma (MM).

112 site for p300/CBP) and AD2 (binding site for CARM1) activation domains of GRIP1 contributed to the sy

113 strates than CARM1, could not substitute for CARM1 to act synergistically with p300 or p/CAF.

114 reviously identified in vitro substrates for CARM1.

115 s a self-regulatory signaling mechanism from CARM1's catalytic domain to its CTD.

116 Furthermore, CARM1-mediated BAF155 methylation affects gene expressio

117 The synergy between GRIP1, CARM1, and Fli-I required the methyltransferase activity

118 criptional synergy among coactivators GRIP1, CARM1, p300 and CoCoA.

119 A ternary complex of GRIP1, CARM1, and p300 or CBP was demonstrated in cultured mamm

120 CoCoA cooperated synergistically with GRIP1, CARM1, and p300 to enhance ER-mediated transcription.

121 sociation of ATP-remodeling factors with HMT CARM1 defines a new component of regulation in the nucle

122 However, CARM1 methylates histone H3, PABP1, AIB1, and a number o

123 However, CARM1-dependent methylation of histone H3 was not observ

124 tor-associated arginine methyltransferase I (CARM1; PRMT4) regulates gene expression by multiple mech

125 These studies identify CARM1 as a potential new target in the treatment of estr

126 ha-regulated cellular processes, implicating CARM1 as a putative epigenetic target in ER-positive bre

127 e H3 tails harboring dimethylation at R17 in CARM1-methylated histone octamers.

128 erves as a unique mechanism for inactivating CARM1-regulated estrogen-dependent gene expression.

129 st, transfection of a catalytically inactive CARM1 methyltransferase mutant did not enhance Tax trans

130 portance of multiple coactivators, including CARM1 and its specific protein methyltransferase activit

131 lear receptor coactivator complex, including CARM1, p300/CBP, and GRIP1 (one of the p160 coactivators

132 Indeed, CARM1 is found to interact with a number of proteins and

133 Nonetheless, these are sites of E2-induced CARM1 activity.

134 vivo, Ser2 or Ser5 phosphorylation inhibits CARM1 activity toward this site in vitro, suggesting tha

135 whereas estrogen stimulation of cyclin D1 is CARM1 independent.

136 of SRC-3 was localized to an arginine in its CARM1 binding region and correlated with decreased estro

137 The methylation of two known CARM1 substrates, poly(A)-binding protein (PABP1) and th

138 Mice lacking CARM1 are small, fail to breathe and die shortly after b

139 ses demonstrate that lungs from mice lacking CARM1 have immature alveolar type II cells and an absenc

140 The lungs of newborn mice lacking CARM1 have substantially reduced airspace compared with

141 alternative transcripts encoding full-length CARM1 (CARM1FL) and CARM1 with exon 15 deleted (CARM1Del

142 his nuclear retention pathway at two levels: CARM1 methylates the coiled-coil domain of p54(nrb), res

143 cts with other proteins that help to mediate CARM1 coactivator function.

144 ed expression of the histone H3R26-methylase CARM1 and is lowered following CARM1 inhibition, indicat

145 In the NUMAC complex, the methylase, CARM1, acquires the ability to covalently modify nucleos

146 egulation via the arginine methyltransferase CARM1 (coactivator-associated arginine methyltransferase

147 The arginine methyltransferase CARM1 (coactivator-associated arginine methyltransferase

148 g the H3-specific arginine methyltransferase CARM1 in individual blastomeres and show that this direc

149 ivator-associated arginine methyltransferase CARM1 is a positive regulator of ER alpha-mediated trans

150 ivator-associated arginine methyltransferase CARM1 is recruited by many different transcription facto

151 we show that the arginine methyltransferase CARM1 methylates BAF155, which differentially influences

152 P or p300, and the histone methyltransferase CARM1 (coactivator-associated arginine methyltransferase

153 arginine-specific histone methyltransferase CARM1.

154 erase p300 and the histone methyltransferase CARM1.

155 0 coactivator, the protein methyltransferase CARM1, and any of the three protein acetyltransferases,

156 00 and CBP and the protein methyltransferase CARM1.

157 vator-associated arginine methyltransferase (CARM1) depends on the methyltransferase activity of CARM

158 vator-associated arginine methyltransferase (CARM1) is a transcriptional coactivator that methylates

159 vator-associated arginine methyltransferase (CARM1/PRMT4), during IFN-gamma-induced MHC-II gene activ

160 vator-associated arginine methyltransferase (CARM1/PRMT4)-mediated transcriptional coactivation and a

161 vator-associated arginine methyltransferase, CARM1, is a positive regulator of transcription.

162 ries of protein arginine methyltransferases, CARM1 and PRMT1, as transcriptional coactivators for nuc

163 Surprisingly, mouse CARM1 expressed in insect and mammalian expression syste

164 he phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl don

165 tive to H3R2 methylation and that PRMT6, not CARM1/PRMT4, is the primary methyltransferase acting on

166 Notably, CARM1 stability is regulated by the SKP2-containing SCF

167 To unbiasedly investigate novel CARM1 PTMs we employed high-resolution top-down mass spe

168 Absence of CARM1 methyltransferase activity led to failure of cells

169 We previously reported that the absence of CARM1 partially blocks thymocyte differentiation at embr

170 In the absence of CARM1, alveolar type II cells show increased proliferati

171 understanding of the mechanism of action of CARM1 in oncogenesis has been limited by a lack of selec

172 These actions of CARM1 work together synergistically to regulate the expo

173 pendent on the methyltransferase activity of CARM1 and the acetyltransferase activity of p/CAF, but n

174 The methyltransferase activity of CARM1 is important for its synergistic coactivator funct

175 eport that the methyltransferase activity of CARM1 is negatively regulated through phosphorylation at

176 its specific chromatin modifying activity of CARM1 necessary for full potentiation of the BSEP locus

177 by inhibiting methyltransferase activity of CARM1, the enzyme responsible for H3R26 methylation, HIV

178 /p300, and the methyltransferase activity of CARM1.

179 depends on the methyltransferase activity of CARM1.

180 I required the methyltransferase activity of CARM1.

181 n required the methyltransferase activity of CARM1.

182 TLV-1 LTR promoter showed the association of CARM1 and methylated histone H3 with the template DNA.

183 BP is sufficient to drive the association of CARM1 with chromatin and methylation of R17 in vivo, whe

184 Our previous finding that automethylation of CARM1 is essential for regulation of transcription and p

185 sults strongly imply that automethylation of CARM1 provides a direct link to couple transcription and

186 In vitro, Tax facilitates the binding of CARM1 to the transcription complex.

187 Our findings suggest that coexpression of CARM1 and ERalpha may provide a better biomarker of well

188 We propose that development of CARM1-specific inhibitors should focus on its N-terminus

189 We demonstrate that dimethylation of CARM1 occurs both in vivo and in vitro and proceeds via

190 w that embryos with a targeted disruption of CARM1 are small in size and die perinatally.

191 We demonstrate that disruption of CARM1 enhances the nuclear retention of mRNAs containing

192 Here we show that other domains of CARM1 are required for the coactivator function of CARM1

193 Here, we examined the effects of CARM1 inhibition on dendritic spine and synapse morpholo

194 on was severely attenuated by elimination of CARM1 or its methyltransferase activity, or by mutation

195 emonstrated that the coactivator function of CARM1 depends both on the methyltransferase activity and

196 are required for the coactivator function of CARM1 in addition to the methyltransferase activity.

197 To elucidate the functions of CARM1 in tumorigenesis, we knocked out CARM1 from severa

198 rue in zebrafish, in which, with the help of CARM1 inhibitor and CARM1 morpholinos, we show that inhi

199 ARM1 KO cell lines enabled identification of CARM1 substrates, notably the SWI/SNF core subunit BAF15

200 To unequivocally establish the importance of CARM1 enzymatic activity in vivo, we generated an enzyme

201 Similarly, pharmacological inhibition of CARM1 activity with the CARM1-specific inhibitor AMI-1 s

202 er, such mutation leads to the inhibition of CARM1 transactivation of estrogen receptor-dependent tra

203 EZM2302 (GSK3359088) is an inhibitor of CARM1 enzymatic activity in biochemical assays (IC50 = 6

204 the first potent and selective inhibitor of CARM1 that exhibits anti-proliferative effects both in v

205 Using a specific small-molecule inhibitor of CARM1-mediated H3R17 methylation in human embryonic stem

206 Thus, small molecule inhibitors of CARM1 will incapacitate all of the enzyme's cellular fun

207 d prostate adenocarcinomas, and knockdown of CARM1 inhibits proliferation of breast and prostate canc

208 This repression leads to increased levels of CARM1 protein and subsequent increases in histone H3 Arg

209 tron microscopy revealing co-localization of CARM1 with post-synaptic density (PSD)-95 protein, a pos

210 e observations, we hypothesized that loss of CARM1 in mouse embryos would inhibit pulmonary cell prol

211 By contrast, we report here that loss of CARM1 results in hyperproliferation of pulmonary epithel

212 The catalytic efficiency (k(cat)/K(m)) of CARM1 toward H3 was at least 1000 times that toward R1 (

213 Although mutation of CARM1's automethylation site did not affect its enzymati

214 Overexpression of CARM1 is implicated in a number of cancers, and it is th

215 studies demonstrated that overexpression of CARM1 wild-type protein resulted in increased Tax transa

216 activity at present, the C-terminal part of CARM1 contains an autonomous activation domain, suggesti

217 our results suggest that phosphorylation of CARM1 serves as a unique mechanism for inactivating CARM

218 dditionally, we find that the recruitment of CARM1 and subsequent histone arginine dimethylation are

219 ermore, phospho-SRC1-mediated recruitment of CARM1 induced prominent asymmetric dimethylation of H3R1

220 The sequential recruitment of CARM1 not only adds a protein arginine methyltransferase

221 The recruitment of CARM1 to the promoter requires endogenous CIITA and resu

222 tivities all reside in the central region of CARM1, which is highly conserved among the entire protei

223 ain, the unique N- and C-terminal regions of CARM1 were also required for enhancement of transcriptio

224 mation and that spatiotemporal regulation of CARM1 activity modulates neuronal connectivity and impro

225 However, the regulation of CARM1 enzymatic activity and substrate specificity remai

226 uronal progenitor specification, the role of CARM1 in any neuronal developmental pathways has been un

227 ter birth, demonstrating the crucial role of CARM1 in development.

228 e genetic evidence for the essential role of CARM1 in estrogen-mediated transcriptional activation.

229 tion is regulated by alternative splicing of CARM1 mRNA to remove exon 15, containing the automethyla

230 High-resolution crystal structures of CARM1 in complex with these compounds confirm a mode of

231 Specific siRNA-mediated suppression of CARM1 expression resulted in precocious dendritic matura

232 Gene targeting of CARM1 in mice has been performed, and knock-out mice, wh

233 nally, we demonstrate that the N-terminus of CARM1 is involved in substrate recognition and nearly in

234 subunits or CARM1 affected transcription of CARM1-regulated, estrogen-responsive genes.

235 Furthermore, either CARM1 knockdown or CARM1 enzyme-deficient mutant knockin resulted in decrea

236 Here, we showed that PRMT5, but not PRMT1 or CARM1, is essential for cell proliferation and PRMT5 def

237 Knockdown of either PAF1c subunits or CARM1 affected transcription of CARM1-regulated, estroge

238 ns of CARM1 in tumorigenesis, we knocked out CARM1 from several breast cancer cell lines using Zinc-F

239 lar level and 6- to 25-fold selectivity over CARM1, PRMT5, and PRMT8.

240 lation increased in cells that overexpressed CARM1.

241 and its downstream coactivators (e.g., p300, CARM1, CoCoA, and Fli-I), which contribute to transcript

242 omoter activation, including CBP/p300, PCAF, CARM1 and GRIP1.

243 These constructs were found to be potent CARM1 inhibitors and also formed stable complexes with t

244 n motifs for three of these enzymes - PRMT1, CARM1 and PRMT9.

245 enerated multiple cell lines in which PRMT1, CARM1 and PRMT5 are inducibly knocked down.

246 at protein arginine methyltransferase PRMT4 (CARM1) methylates TP2 at Arg(71), Arg(75), and Arg(92) r

247 ss spectrometry approach to globally profile CARM1 substrates in breast cancer cell lines.

248 at phosphorylation at Ser(217) also promoted CARM1 cytoplasmic localization and that this translocati

249 one H3K18 residues, which, in turn, promotes CARM1 methylation activity on H3R17 residues to enhance

250 Comparative analysis of the published CARM1 crystal structures reveals that the hydroxyl group

251 Affinity-purified CARM1 methylated recombinant chick H3, which is free of

252 Reciprocally, CARM1 stimulates the ATPase activity of BRG1, a key comp

253 18 and K23, but not K14, tethers recombinant CARM1 to the H3 tail and allows it to act as a more effi

254 Specific RNA interference reduced CARM1 expression as well as MHC-II expression.

255 XR regulatory element ligand, CDCA, requires CARM1 activity.

256 or further understanding the biological role CARM1 plays in cancer and other diseases.

257 identify a new signalling axis of AMPK-SKP2-CARM1 in the regulation of autophagy induction after nut

258 In the current study, CARM1 cooperated with GRIP1 to enhance steroid hormone-d

259 methylate different protein substrates than CARM1, could not substitute for CARM1 to act synergistic

260 These results demonstrate that CARM1 plays a significant role in promoting the differen

261 Our findings demonstrate that CARM1-dependent histone arginine methylation is a crucia

262 aken together, this report demonstrates that CARM1 is a key epigenetic regulator of hematopoiesis tha

263 Together, our data provide evidence that CARM1 enhances Tax transactivation of the HTLV-1 LTR thr

264 We propose that CARM1 is a dual-function coactivator, as it not only act

265 It has been proposed that CARM1 has functions that are independent of its enzymati

266 Here, we report that CARM1 also methylates Arg-2142 within the C-terminal GRI

267 In this study, we report that CARM1 function is regulated by phosphorylation at Ser(21

268 Cancer Cell, Wang and colleagues report that CARM1, a protein arginine methyltransferase, specificall

269 Genome-wide analyses reveal that CARM1 exerts transcriptional co-activator function on au

270 r and the endogenous CD44 gene revealed that CARM1 promotes exon skipping in an enzyme-dependent mann

271 Here, we show that CARM1 is essential for estrogen-induced cell cycle progr

272 cells in a CARM1-sufficient host showed that CARM1 is required cell autonomously in hematopoietic cel

273 ) FL cells on OP9-DL1 monolayers showed that CARM1 is required for survival of hematopoietic progenit

274 Here it is shown that CARM1 binds to beta-catenin and can function in synergy

275 Previous work has shown that CARM1 can methylate CBP at three arginine residues.

276 These results suggest that CARM1 is a post-synaptic protein that plays roles in den

277 results demonstrate for the first time that CARM1 inhibits pulmonary cell proliferation and is requi

278 The CARM1 KO cell lines enabled identification of CARM1 subs

279 nction in neurons, little is known about the CARM1 cellular location and its role in dendritic matura

280 The CBP/p300 acetylase and the CARM1 methyltransferase can positively regulate the expr

281 ed reflective of the transition state at the CARM1 active site.

282 ild-type CBP and a mutant of CBP lacking the CARM1-targeted arginine residues (R3A), we show that arg

283 The crystal structures of the CARM1 catalytic core in the apo and holo states reveal c

284 ompounds such as JQ1 or vorinostat/SAHA, the CARM1 inhibitor achieved synergistic effects on HIV-1 ac

285 ogical inhibition of CARM1 activity with the CARM1-specific inhibitor AMI-1 significantly increased s

286 Thus, CARM1 functions as a corepressor in cyclic adenosine mon

287 Thus, CARM1 is a critical factor in the pathway of estrogen-st

288 Thus, CARM1, which plays a role in transcriptional activation

289 on additional unknown proteins that bind to CARM1.

290 Fli-I bound to CARM1, GRIP1, and NRs and cooperated synergistically wit

291 stimulation, the E2F1 promoter is subject to CARM1-dependent dimethylation on histone H3 arginine 17

292 In human breast tumors, CARM1 expression positively correlated with ERalpha leve

293 EZM2302 demonstrates dose-dependent in vivo CARM1 inhibition and anti-tumor activity in an MM xenogr

294 In vivo, CARM1 and BRG1 coassemble on an estrogen receptor (ER)-t

295 th an intact FXR regulatory element, whereas CARM1 failed to transactivate the BSEP promoter with a m

296 The current study tested whether CARM1 can cooperate with other types of coactivator prot

297 scription activation, the mechanism by which CARM1 activates transcription remains unclear.

298 To understand the mechanism by which CARM1 functions, we sought to isolate its substrates.

299 was recruited to the ER promoter along with CARM1, CBP, c-Jun, and Sp1 and that this multifactor com

300 and NRs and cooperated synergistically with CARM1 and GRIP1 to enhance NR function.